The Patent Finder
TP

Tagworks Pharmaceuticals B.V.

First filing 2011
OverviewNotableFeesChangesFamiliesPatent listSources & methods

15 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2031
Next term end
9
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Bio-Orthogonal Drug Activation US 9,421,274
The most cited patent in this portfolio, cited by 59 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Ends May 2032 · High confidence
Also notable
Bio-Orthogonal Drug Activation US 10,376,594
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Ends Oct 2031 · High confidence
Also notable
Chemically Cleavable Group US 10,927,139
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2033.
Ends Nov 2033 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Bio-Orthogonal Drug Activation (US 10,376,594) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Bio-Orthogonal Drug Activation (US 11,857,636) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 22, 2026

What they patent

The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,463,256Pretargeting Kit, Method and Agents Used Therein
In force
 · High confidence
In forceHigh confidence
US 10,004,810Bio-Orthogonal Drug Activation
In force
 · High confidence
In forceHigh confidence
US 10,376,594Bio-Orthogonal Drug Activation
In force
 · High confidence
In forceHigh confidence
US 10,967,069Bio-Orthogonal Drug Activation
In force
 · High confidence
In forceHigh confidence
US 11,857,636Bio-Orthogonal Drug Activation
In force
 · High confidence
In forceHigh confidence
US 9,427,482Agents for Clearing Biomolecules from Circulation
In force
 · High confidence
In forceHigh confidence
US 9,913,921Pretargeting Kit for Imaging or Therapy Comprising a Trans-Cyclooctene Dienophile and a Diene
In force
 · High confidence
In forceHigh confidence
US 9,421,274Bio-Orthogonal Drug Activation
In force
 · High confidence
In forceHigh confidence
US 9,931,408Bio-Orthogonal Drug Activation
In force
 · High confidence
In forceHigh confidence
US 10,927,139Chemically Cleavable Group
In force
 · High confidence
In forceHigh confidence
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 10 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited